As BiomEdit’s newest project to enter pivotal development, CPerf LLV* (BE-101) represents one of our most advanced and promising assets. Its demonstrated successes, both in vitro and in vivo, validate our approach and the suitability of our platform to address unmet needs in animal health. For this reason, we’re proud to share the video below, which explains the technology that forms the foundation for the CPerf LLV* (BE-101) project.
Please note that the video describes a scientific project concept and is not a description of a marketed product.
For further information, see the following references:
- Gangaiah D, et al. In silico, in vitro and in vivo safety evaluation of Limosilactobacillus reuteri strains ATCC PTA-126787 & ATCC PTA-126788 for potential probiotic applications. PLoS ONE. (2022) 17(1): e0262663.
- Gangaiah D, et al. Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis. MicrobiologyOpen. (2022) 11:e1270.
